Clarity launches $121 million fully underwritten equity raising
Posted: 11 April 2024 Clarity Pharmaceuticals (ASX:CU6) (“Clarity” or “Company”) a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce a fully…
VivaZome Therapeutics and La Trobe University to collaborate on development of extracellular vesicle therapy for treatment of stroke
Posted: 11 April 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke…
Cartherics enters into Collaborative Research Agreement with TiCARos
Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess…
CARTHERICS EXECUTES OPTION AGREEMENT WITH THE OHIO STATE UNIVERSITY
Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…
INOVIQ strengthens exosome leadership with new patent application
Posted: 21 March 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has expanded its exosome intellectual property (IP) portfolio by filing an Australian Provisional Patent Application (APPA) covering its cutting-edge EXO-ACE technology for large…
VivaZome Therapeutics and La Trobe University to collaborate on development of extracellular vesicle therapy for treatment of stroke
Posted: 21 March 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke in the…
Cartherics executes option agreement with the Ohio State University: Tissue factor as a novel target for CAR-NK cells
Posted 20 March 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…
Protein discovery sparks treatment hope for aggressive cancer
Posted: 15 March 2024 Researchers have found a new way to potentially treat one of the most common forms of acute lymphoblastic leukaemia. The study, led by WEHI and the Peter MacCallum Cancer Centre, was able to kill…
DIMERIX SUCCESSFULLY PASSES EFFICACY INTERIM ANALYSIS IN ACTION3 PHASE 3 STUDY FOR FSGS KIDNEY DISEASE
Posted: 12 March 2024 Dimerix Limited (ASX: DXB, “Dimerix”), today announced that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) was successful in the pre-specified interim analysis of the proteinuria (efficacy) endpoint…
Avecho receives Ethics Approval for amendments to Phase III Insomnia Clinical Trial
Posted: 12 March 2024 Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), a biotechnology company focused on developing and commercialising innovative products using its proprietary Tocopheryl Phosphate Mixture (“TPM®”) drug delivery system, is pleased to announce it…
La Trobe and Healthscope invest in health skills
Posted: 12 March 2024 Furthering La Trobe University’s commitment to world-class health innovation and excellence in education, La Trobe Private Hospital provides students and researchers with enhanced opportunities to develop job-ready clinical skills, while offering better health outcomes…
Cynata’s drug reduces wound surface area in diabetic foot ulcers
Posted: 12 March 2024 Cynata Therapeutics (ASX:CYP) has also updated the market on the progress of its diabetic foot ulcers clinical trial. Cynata said it has completed its initial analysis of wound surface area in the first 16 patients…
